Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,733.64
(
0.51%
)
US TECH 100
24,149.60
(
0.56%
)
Dow Jones
47,182.43
(
0.50%
)
Brent Oil
99.41
(
1.12%
)
Bitcoin
74,095.23
(
-1.00%
)
News Focus
News Focus
Post# of 257251
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

zipjet

Send PM Follow Ignore
Followers 36
Posts 2637
Boards Moderated 0
Alias Born 10/06/2003

zipjet

Re: 10nisman post# 111373

Thursday, 12/23/2010 12:04:31 PM

Thursday, December 23, 2010 12:04:31 PM

Post# of 257251

This response supports Teva's belief that even slight changes to a glatiramoid like Copaxone® can significantly and unpredictably influence the efficacy, toxicity and immunogenicity profile of the compound.



Ya gotta love their "spin" capacity.

This looks good for MNTA for two reasons. There will not be an alternative-C diluting the C-market. FDA's sensitivity to "sameness" plays to the MNTA advantage.

ij

There are times when rules and precedents cannot be broken; others when they cannot be adhered to with safety. (Thomas Joplin)

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now